AVIR Green Hills Biotechnology AG

Quick facts

Phase 2 pipeline

• GHB11L1
  GHB11L1 is a therapeutic antibody targeting a viral or cellular antigen to enhance immune response against infection or disease.

Phase 1 pipeline

• GHB01L1
• GHB04L1
• GHB16L2

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AVIR Green Hills Biotechnology AG portfolio CI brief
• AVIR Green Hills Biotechnology AG pipeline updates RSS

Related

• Sector hub: All tracked pharma companies